Navigation

2006/018 100th NICE technology appraisal guidance offers new hope for people with colon cancer

The National Institute for Health and Care Excellence (NICE) has today (26 April 2006) published its 100th technology appraisal guidance. The guidance to the NHS in England and Wales on the use of capecitabine and oxaliplatin for the adjuvant treatment of patients with stage III (Dukes' C)* colon cancer following surgery for the condition, recommends that the drugs should be considered as options for the adjuvant treatment of patients as follows:

  • capecitabine as monotherapy
  • oxaliplatin in combination with 5-fluorouracil and folinic acid.

This page was last updated: 03 August 2007

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.